Proof-of-Concept Trial
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
PR-M11-20-014Nov 18, 2020
Drug Development
New NASH Treatment Achieves Positive Phase III Results
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M02-19-NI-018Feb 21, 2019